Novel aerosol formulation containing a polar fluorinated molecule
申请人:——
公开号:US20030194378A1
公开(公告)日:2003-10-16
The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.
NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE
申请人:AstraZeneca AB
公开号:EP1303258A1
公开(公告)日:2003-04-23
[EN] NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE<br/>[FR] NOUVELLE PREPARATION EN AEROSOL CONTENANT UNE MOLECULE FLUOREE POLAIRE
申请人:ASTRAZENECA AB
公开号:WO2002003958A1
公开(公告)日:2002-01-17
The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.